Preoperative radiation improved T-cell infiltration in patients with HR+ HER2- breast cancer when administered in combination ...
GSK’s B7-H3 targeted antibody drug conjugate risvutatug rezetecan has received FDA Orphan Drug Designation for small cell ...
Presented at 2025 SABCS, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease ...
The results from HER2CLIMB-05 study, presented at the 2025 SABCS annual meeting, demonstrated that tucatinib (TUKYSA) added ...
One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali ...
Arcellx’s Phase 2 iMMagine 1 trial of anito cel in heavily pretreated multiple myeloma delivered a 96% response rate, 74% ...
Early Phase 1b data for enozertinib, presented at the ESMO Asia Congress 2025, show strong systemic and intracranial activity ...
New clinical data presented at the 67th ASH Annual Meeting indicated that Lunsumio could be a strong candidate for earlier ...
Harvard scientists have defined the exact DNA cross-link created by colibactin, a gut microbial toxin associated with ...
The FDA has approved pembrolizumab (Keytruda) or pembrolizumab Qlex with enfortumab vedotin (Padcev) as the first perioperative regimen for cisplatin-ineligible muscle-invasive bladder cancer. In the ...
The FDA has granted accelerated approval to sevabertinib (Hyrnuo), for previously treated HER2-mutated metastatic non-squamous non-small cell lung cancer, based on strong activity in the Phase I/II ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback